Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt 0.06
BSX's Cash to Debt is ranked lower than
56% of the 475 Companies
in the Global Medical Devices industry.

( Industry Median: 2.09 vs. BSX: 0.06 )
BSX' s 10-Year Cash to Debt Range
Min: 0.03   Max: 4.11
Current: 0.06

0.03
4.11
Equity to Asset 0.40
BSX's Equity to Asset is ranked higher than
52% of the 446 Companies
in the Global Medical Devices industry.

( Industry Median: 0.64 vs. BSX: 0.40 )
BSX' s 10-Year Equity to Asset Range
Min: 0.18   Max: 0.79
Current: 0.4

0.18
0.79
Interest Coverage 0.37
BSX's Interest Coverage is ranked lower than
59% of the 267 Companies
in the Global Medical Devices industry.

( Industry Median: 235.10 vs. BSX: 0.37 )
BSX' s 10-Year Interest Coverage Range
Min: 0.37   Max: 65
Current: 0.37

0.37
65
F-Score: 6
Z-Score: 0.94
M-Score: -2.74
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating margin (%) 4.34
BSX's Operating margin (%) is ranked higher than
72% of the 459 Companies
in the Global Medical Devices industry.

( Industry Median: 5.91 vs. BSX: 4.34 )
BSX' s 10-Year Operating margin (%) Range
Min: -53.36   Max: 28.95
Current: 4.34

-53.36
28.95
Net-margin (%) 3.93
BSX's Net-margin (%) is ranked higher than
73% of the 459 Companies
in the Global Medical Devices industry.

( Industry Median: 4.15 vs. BSX: 3.93 )
BSX' s 10-Year Net-margin (%) Range
Min: -56.12   Max: 18.88
Current: 3.93

-56.12
18.88
ROE (%) 4.38
BSX's ROE (%) is ranked higher than
71% of the 443 Companies
in the Global Medical Devices industry.

( Industry Median: 5.20 vs. BSX: 4.38 )
BSX' s 10-Year ROE (%) Range
Min: -44.65   Max: 30.84
Current: 4.38

-44.65
30.84
ROA (%) 1.73
BSX's ROA (%) is ranked higher than
71% of the 475 Companies
in the Global Medical Devices industry.

( Industry Median: 2.77 vs. BSX: 1.73 )
BSX' s 10-Year ROA (%) Range
Min: -21.16   Max: 15.31
Current: 1.73

-21.16
15.31
ROC (Joel Greenblatt) (%) 12.30
BSX's ROC (Joel Greenblatt) (%) is ranked higher than
76% of the 473 Companies
in the Global Medical Devices industry.

( Industry Median: 9.15 vs. BSX: 12.30 )
BSX' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -145.85   Max: 139.6
Current: 12.3

-145.85
139.6
Revenue Growth (3Y)(%) 1.20
BSX's Revenue Growth (3Y)(%) is ranked higher than
68% of the 340 Companies
in the Global Medical Devices industry.

( Industry Median: 5.00 vs. BSX: 1.20 )
BSX' s 10-Year Revenue Growth (3Y)(%) Range
Min: -10.5   Max: 28.9
Current: 1.2

-10.5
28.9
EBITDA Growth (3Y)(%) 80.70
BSX's EBITDA Growth (3Y)(%) is ranked higher than
98% of the 314 Companies
in the Global Medical Devices industry.

( Industry Median: 1.60 vs. BSX: 80.70 )
BSX' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -72   Max: 283.2
Current: 80.7

-72
283.2
EPS Growth (3Y)(%) -49.50
BSX's EPS Growth (3Y)(%) is ranked higher than
53% of the 304 Companies
in the Global Medical Devices industry.

( Industry Median: 2.70 vs. BSX: -49.50 )
BSX' s 10-Year EPS Growth (3Y)(%) Range
Min: -49.5   Max: 124.6
Current: -49.5

-49.5
124.6
» BSX's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q4 2013

BSX Guru Trades in Q4 2013

Ray Dalio 123,584 sh (New)
Jeremy Grantham 78,020 sh (New)
Steven Cohen 2,984,052 sh (+917.36%)
Michael Price 2,000,000 sh (+17.65%)
Diamond Hill Capital 21,034,396 sh (+1.76%)
Steven Cohen 1,657,400 sh (unchged)
Paul Tudor Jones Sold Out
Joel Greenblatt Sold Out
PRIMECAP Management 48,405,219 sh (-0.53%)
Mario Gabelli 2,201,305 sh (-1.5%)
Vanguard Health Care Fund 36,787,000 sh (-3.8%)
Jim Simons 4,358,620 sh (-9.26%)
Dodge & Cox 45,938,468 sh (-22.34%)
Leon Cooperman 8,533,099 sh (-36.64%)
» More
Q1 2014

BSX Guru Trades in Q1 2014

Paul Tudor Jones 17,944 sh (New)
PRIMECAP Management 49,351,819 sh (+1.96%)
Diamond Hill Capital 21,043,292 sh (+0.04%)
Vanguard Health Care Fund 36,787,000 sh (unchged)
Leon Cooperman 8,533,099 sh (unchged)
Michael Price 2,000,000 sh (unchged)
Jeremy Grantham Sold Out
Dodge & Cox 45,224,168 sh (-1.55%)
Mario Gabelli 2,099,005 sh (-4.65%)
Steven Cohen 2,042,403 sh (-31.56%)
Jim Simons 1,494,405 sh (-65.71%)
Ray Dalio 36,884 sh (-70.15%)
» More
Q2 2014

BSX Guru Trades in Q2 2014

Paul Tudor Jones 27,040 sh (+50.69%)
Vanguard Health Care Fund 42,743,200 sh (+16.19%)
Diamond Hill Capital 21,615,122 sh (+2.72%)
Michael Price 2,000,000 sh (unchged)
Ray Dalio Sold Out
Dodge & Cox 44,872,818 sh (-0.78%)
PRIMECAP Management 48,452,019 sh (-1.82%)
Mario Gabelli 1,785,836 sh (-14.92%)
Leon Cooperman 6,549,479 sh (-23.25%)
Jim Simons 540,205 sh (-63.85%)
» More
Q3 2014

BSX Guru Trades in Q3 2014

Ray Dalio 61,384 sh (New)
Steven Cohen 2,523,500 sh (New)
Jim Simons 2,209,905 sh (+309.09%)
Paul Tudor Jones 89,341 sh (+230.4%)
Vanguard Health Care Fund 51,242,050 sh (+19.88%)
Diamond Hill Capital 23,137,833 sh (+7.04%)
Michael Price 2,000,000 sh (unchged)
Leon Cooperman Sold Out
Dodge & Cox 44,458,338 sh (-0.92%)
PRIMECAP Management 47,079,199 sh (-2.83%)
Mario Gabelli 1,704,036 sh (-4.58%)
» More
» Details

Insider Trades

Latest Guru Trades with BSX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Leon Cooperman 2014-09-30 Sold Out 1.1%$11.92 - $13.29 $ 13.134%0
Vanguard Health Care Fund 2014-09-30 Add 19.88%0.25%$11.92 - $13.29 $ 13.134%51242050
Ray Dalio 2014-09-30 New Buy0.01%$11.92 - $13.29 $ 13.134%61384
Leon Cooperman 2014-06-30 Reduce -23.25%0.35%$12.58 - $13.77 $ 13.131%6549479
Vanguard Health Care Fund 2014-06-30 Add 16.19%0.2%$12.58 - $13.77 $ 13.131%42743200
Ray Dalio 2014-06-30 Sold Out $12.58 - $13.77 $ 13.131%0
Ray Dalio 2014-03-31 Reduce -70.15%0.01%$11.91 - $13.98 $ 13.130%36884
Leon Cooperman 2013-12-31 Reduce -36.64%0.88%$11.18 - $12.38 $ 13.1311%8533099
Michael Price 2013-12-31 Add 17.65%0.47%$11.18 - $12.38 $ 13.1311%2000000
Dodge & Cox 2013-12-31 Reduce -22.34%0.18%$11.18 - $12.38 $ 13.1311%45938468
Joel Greenblatt 2013-12-31 Sold Out 0.01%$11.18 - $12.38 $ 13.1311%0
Ray Dalio 2013-12-31 New Buy0.01%$11.18 - $12.38 $ 13.1311%123584
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Guru Investment Theses on Boston Scientific Inc

Diamond Hill Capital Comments on Boston Scientific Corp - Oct 17, 2014

Shares of Boston Scientific Corp. (BSX) declined as investors focused on potential liabilities stemming from legal disputes. We continue to see improvement in revenue trends and believe they will be key factors in closing the discount to our estimate of intrinsic value over time.

From Diamond Hill Capital (Trades, Portfolio)'s Select Fund Third Quarter 2014 Commentary.

Check out Diamond Hill Capital latest stock trades

Diamond Hill Capital Comments on Boston Scientific Corp - Jul 25, 2014

•Medical device manufacturer Boston Scientific Corp. (BSX) reported solid earnings for the first quarter but investors focused on near-term headwinds in the cardiac-rhythm management business. The company also announced a delay in potential approval for its Watchman’s heart device. Given the breadth of the company’s pipeline, potential for margin upside, and attractive valuation, we continue to like the outlook for the shares going forward.

From Diamond Hill Capital (Trades, Portfolio)'s Select Fund Second Quarter 2014 Commentary.

Check out Diamond Hill Capital latest stock trades

Diamond Hill Capital Comments on Boston Scientific Corp - Jun 26, 2014

Medical device manufacturer Boston Scientific Corp. (BSX) benefitted from continued revenue acceleration and the launch of a new high margin stent with the potential for sizeable share gains.



From Diamond Hill Capital's Select Fund Commentary – First Quarter 2014.



Check out Diamond Hill Capital latest stock trades

Diamond Hill Capital Comments on Boston Scientific Corp - Jan 15, 2014

Boston Scientific Corp. (BSX), a medical device manufacturer, recently reported its first quarter of growth in more than three years, while also raising its earnings outlook. An emerging pipeline of new products offers the potential for continued improvement and the potential to return to mid-single digit revenue growth.

From Diamond Hill Capital (Trades, Portfolio) Large Cap Fund third quarter 2013 commentary.

Check out Diamond Hill Capital latest stock trades

Top Ranked Articles about Boston Scientific Inc

Diamond Hill Capital Comments on Boston Scientific Corp
Shares of Boston Scientific Corp. (BSX) declined as investors focused on potential liabilities stemming from legal disputes. We continue to see improvement in revenue trends and believe they will be key factors in closing the discount to our estimate of intrinsic value over time. Read more...
Diamond Hill Capital Comments on Boston Scientific Corp
•Medical device manufacturer Boston Scientific Corp. (BSX) reported solid earnings for the first quarter but investors focused on near-term headwinds in the cardiac-rhythm management business. The company also announced a delay in potential approval for its Watchman’s heart device. Given the breadth of the company’s pipeline, potential for margin upside, and attractive valuation, we continue to like the outlook for the shares going forward. Read more...
Diamond Hill Capital Comments on Boston Scientific Corp
Medical device manufacturer Boston Scientific Corp. (BSX) benefitted from continued revenue acceleration and the launch of a new high margin stent with the potential for sizeable share gains. Read more...
Diamond Hill Capital Comments on Boston Scientific Corp
Boston Scientific Corp. (BSX), a medical device manufacturer, recently reported its first quarter of growth in more than three years, while also raising its earnings outlook. An emerging pipeline of new products offers the potential for continued improvement and the potential to return to mid-single digit revenue growth. Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 62.20
BSX's P/E(ttm) is ranked higher than
75% of the 510 Companies
in the Global Medical Devices industry.

( Industry Median: 84.60 vs. BSX: 62.20 )
BSX' s 10-Year P/E(ttm) Range
Min: 14.05   Max: 89.4
Current: 62.2

14.05
89.4
P/B 2.60
BSX's P/B is ranked higher than
78% of the 510 Companies
in the Global Medical Devices industry.

( Industry Median: 3.95 vs. BSX: 2.60 )
BSX' s 10-Year P/B Range
Min: 0.59   Max: 11.67
Current: 2.6

0.59
11.67
P/S 2.40
BSX's P/S is ranked higher than
75% of the 510 Companies
in the Global Medical Devices industry.

( Industry Median: 3.57 vs. BSX: 2.40 )
BSX' s 10-Year P/S Range
Min: 1.02   Max: 10.12
Current: 2.4

1.02
10.12
PFCF 21.88
BSX's PFCF is ranked higher than
92% of the 510 Companies
in the Global Medical Devices industry.

( Industry Median: 9999.00 vs. BSX: 21.88 )
BSX' s 10-Year PFCF Range
Min: 7.25   Max: 192.5
Current: 21.88

7.25
192.5
EV-to-EBIT 67.37
BSX's EV-to-EBIT is ranked higher than
73% of the 510 Companies
in the Global Medical Devices industry.

( Industry Median: 61.55 vs. BSX: 67.37 )
BSX' s 10-Year EV-to-EBIT Range
Min: -1722.5   Max: 184.9
Current: 67.37

-1722.5
184.9
Current Ratio 1.74
BSX's Current Ratio is ranked higher than
57% of the 467 Companies
in the Global Medical Devices industry.

( Industry Median: 2.79 vs. BSX: 1.74 )
BSX' s 10-Year Current Ratio Range
Min: 0.52   Max: 3.57
Current: 1.74

0.52
3.57
Quick Ratio 1.20
BSX's Quick Ratio is ranked higher than
58% of the 467 Companies
in the Global Medical Devices industry.

( Industry Median: 2.01 vs. BSX: 1.20 )
BSX' s 10-Year Quick Ratio Range
Min: 0.33   Max: 2.82
Current: 1.2

0.33
2.82

Valuation & Return

vs
industry
vs
history
Price/DCF (Projected) 1.59
BSX's Price/DCF (Projected) is ranked higher than
92% of the 510 Companies
in the Global Medical Devices industry.

( Industry Median: 9999.00 vs. BSX: 1.59 )
BSX' s 10-Year Price/DCF (Projected) Range
Min: 0.5   Max: 5.76
Current: 1.59

0.5
5.76
Price/Median PS Value 1.09
BSX's Price/Median PS Value is ranked higher than
75% of the 510 Companies
in the Global Medical Devices industry.

( Industry Median: 1.21 vs. BSX: 1.09 )
BSX' s 10-Year Price/Median PS Value Range
Min: 0.48   Max: 4.3
Current: 1.09

0.48
4.3
Earnings Yield (Greenblatt) 1.50
BSX's Earnings Yield (Greenblatt) is ranked higher than
72% of the 469 Companies
in the Global Medical Devices industry.

( Industry Median: 2.40 vs. BSX: 1.50 )
BSX' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.5   Max: 9
Current: 1.5

0.5
9
Forward Rate of Return (Yacktman) 51.89
BSX's Forward Rate of Return (Yacktman) is ranked higher than
98% of the 213 Companies
in the Global Medical Devices industry.

( Industry Median: 5.52 vs. BSX: 51.89 )
BSX' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 3.1   Max: 49.3
Current: 51.89

3.1
49.3

Business Description

Industry: Medical Devices » Medical Devices
Compare:MDT, SYK, SMA, ZMH, STJ » details
Traded in other countries:BSX.Germany,
Boston Scientific Inc is a developer, manufacturer and marketer of medical devices that are used in a broad range of interventional medical specialties. The Company's products were offered for sale by seven core businesses - Interventional Cardiology, Cardiac Rhythm Management (CRM), Endoscopy, Peripheral Interventions (PI), Urology and Women's Health, Neuromodulation, and Electrophysiology (EP). market a broad portfolio of internally-developed and self-manufactured drug-eluting stents including the Promus Element and Promus Element Plus everolimus-eluting stents, as well as its TAXUS Element and Ion paclitaxel-eluting stents. The Company sell various products designed to treat patients with peripheral disease (disease which appears in blood vessels other than in the heart and in the biliary tree), including a broad line of medical devices used in percutaneous transluminal angioplasty (PTA) and peripheral vascular stenting. Its peripheral product offerings include stents, balloon catheters, wires, peripheral embolization devices and vena cava filters. Its peripheral angioplasty balloon technology includes its next-generation Mustang PTA balloon, its Coyote balloon catheter, a deliverable and ultra-low profile balloon dilatation catheter designed for a wide range of peripheral angioplasty procedures, and its Charger PTA Balloon Catheter, a 0.035" percutaneous transluminal angioplasty balloon catheter designed for post-stent dilatation as well as conventional balloon angioplasty to open blocked peripheral arteries. The Company also sell products designed to treat patients with non-vascular disease (disease that appears outside the blood system). Its non-vascular suite of products includes biliary stents, drainage catheters and micro-puncture sets designed to treat, diagnose and ease various forms of benign and malignant tumors. The Company continue to market its extensive line of Interventional Oncology product solutions, including the recently launched Renegade HI-FLO Fathom microcatheter and guidewire system and Interlock - 35 Fibered IDC Occlusion System for peripheral embolization. The Company develop, manufacture and market a variety of implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities, including: Implantable cardioverter defibrillator (ICD), Implantable pacemaker systems. During 2013, the company marketed its products to over 13,000 hospitals, clinics, outpatient facilities and medical offices in approximately 100 countries. The Company is subject to various environmental laws, directives and regulations both in the U.S. and abroad. Its operations, like those of other medical device companies, involve the use of substances regulated under environmental laws, primarily in manufacturing and sterilization processes.
» More Articles for BSX

Headlines

Articles On GuruFocus.com
Edwards Lifesciences a Gold Standard in the Market Dec 16 2014 
Boston Scientific Lost the First Place in Innovation Dec 11 2014 
Diamond Hill Capital Comments on Boston Scientific Corp Oct 17 2014 
Diamond Hill Capital Comments on Boston Scientific Corp Jul 25 2014 
Diamond Hill Capital Comments on Boston Scientific Corp Jun 26 2014 
Diamond Hill Select Fund Commentary – First Quarter 2014 Jun 25 2014 
Diamond Hill Capital Comments on Boston Scientific Corp Jan 15 2014 
Vanguard Health Care Fund Selling Update Oct 30 2013 
Diamond Hill Funds Q3 Market Review and Large-Cap Fund Commentary Oct 29 2013 
Weekly CFO Sells Highlight: BSX, RKUS, MCRL, LRAD and SWKS Sep 08 2013 


More From Other Websites
Omega Advisors eliminates position in Boston Scientific Dec 23 2014
IPO Stock Watch: Medical Device Maker Nevro Hits High Dec 22 2014
Boston Scientific To Participate In 33rd Annual J.P. Morgan Healthcare Conference Dec 22 2014
Boston Scientific To Participate In 33rd Annual J.P. Morgan Healthcare Conference Dec 22 2014
Puts surging in Boston Scientific Dec 19 2014
Boston Scientific To Participate In Goldman Sachs CEOs Unscripted Healthcare Conference Dec 18 2014
Boston Scientific To Participate In Goldman Sachs CEOs Unscripted Healthcare Conference Dec 18 2014
Volcano Up 55% On Acquisition News Dec 17 2014
New Data Presented At NANS 2014 Demonstrate Long-Term, Low Back Pain Relief With Boston Scientific... Dec 12 2014
New Data Presented At NANS 2014 Demonstrate Long-Term, Low Back Pain Relief With Boston Scientific... Dec 12 2014
Boston Scientific Lost the First Place in Innovation Dec 11 2014
Bears taking aim at Boston Scientific Dec 02 2014
Boston Scientific to pay damages in transvaginal mesh case Nov 20 2014
Boston Scientific Vaginal-Mesh Victims Win $18.5 Million Nov 20 2014
J&J demands $7.2 bln from Boston Scientific as trial begins Nov 20 2014
Boston Scientific ordered to pay $14.5 mln for transvaginal mesh injuries Nov 20 2014
Boston Scientific (BSX) Spotted As Roof Leaker Today Nov 20 2014
Boston Scientific Earns Top Marks In Corporate Equality Index Nov 19 2014
Boston Scientific Put Mesh Sales Ahead of Safety: Lawyer Nov 19 2014
Boston Scientific (BSX) Is Water-Logged And Getting Wetter Today Nov 19 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK